| Cystic Fibrosis
Kalydeco vs Trikafta
Side-by-side clinical, coverage, and cost comparison for cystic fibrosis.Deep comparison between: Kalydeco vs Trikafta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrikafta has a higher rate of injection site reactions vs Kalydeco based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trikafta but not Kalydeco, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kalydeco
Trikafta
At A Glance
Oral
Every 12 hours
CFTR potentiator
Oral
Twice daily
CFTR modulator
Indications
- Cystic Fibrosis
- Cystic Fibrosis
Dosing
Cystic Fibrosis Weight-based dosing every 12 hours with fat-containing food: oral granules from 5.8 mg (1 to <2 months, >=3 kg) up to 75 mg (6 months to <6 years, >=14 kg); 150 mg tablet for patients >=6 years; dose reduced to once daily for moderate hepatic impairment or concomitant moderate CYP3A inhibitors (>=6 months), and to twice weekly for strong CYP3A inhibitors (>=6 months).
Cystic Fibrosis Weight-based oral doses (granules for ages 2 to <6, tablets for ages 6+) taken as a morning elexacaftor/tezacaftor/ivacaftor combination dose plus an evening ivacaftor dose approximately 12 hours apart with fat-containing food; dose reduced for moderate hepatic impairment and concomitant CYP3A inhibitors; not for use in severe hepatic impairment.
Contraindications
—
—
Adverse Reactions
Most common (>=8%) Headache, oropharyngeal pain, upper respiratory tract infection, nasal congestion, abdominal pain, nasopharyngitis, diarrhea, rash, nausea, dizziness
Serious Abdominal pain, increased hepatic enzymes, hypoglycemia, transaminase elevations
Postmarketing Anaphylaxis, intracranial hypertension, anxiety, depression, suicidal ideation and behavior, insomnia
Most common (>=5%) Headache, upper respiratory tract infection, abdominal pain, diarrhea, rash, alanine aminotransferase increased, nasal congestion, blood creatine phosphokinase increased, aspartate aminotransferase increased, rhinorrhea, rhinitis, influenza, sinusitis, blood bilirubin increased
Serious Drug-induced liver injury and liver failure, hypersensitivity reactions including anaphylaxis, intracranial hypertension, neuropsychiatric events including suicidal thoughts and behaviors, cataracts
Postmarketing Liver injury, fatal liver failure, liver transplantation, anaphylaxis, angioedema, intracranial hypertension, anxiety, depression, suicidal ideation and behavior, insomnia
Pharmacology
Ivacaftor is a CFTR potentiator that facilitates increased chloride transport by potentiating the channel open probability (gating) of CFTR protein located at the epithelial cell surface; clinical benefit requires at least one ivacaftor-responsive CFTR mutation identified by clinical and/or in vitro assay data.
CFTR modulator triple combination; elexacaftor and tezacaftor are CFTR correctors that bind to different sites on the CFTR protein to facilitate cellular processing and trafficking of mutant CFTR (including F508del-CFTR) to the cell surface, while ivacaftor is a CFTR potentiator that enhances channel open probability at the cell surface, together resulting in increased CFTR quantity and function as measured by CFTR-mediated chloride transport and sweat chloride reduction.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kalydeco
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Trikafta
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Kalydeco
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (1/8)
Trikafta
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Kalydeco
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Trikafta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Cystic Fibrosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Cystic Fibrosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KalydecoView full Kalydeco profile
TrikaftaView full Trikafta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.